Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 2/20 | 0.50 |
| ▸ | F3 | P13726 | 2/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206725 | 0.84 | AHR (0.48) | F7F3AHRLTA4HNR4A2 | |
| SCHEMBL208727 | 0.73 | GAA (0.51) | F7F3F11ALDH1A1HPGD | |
| SCHEMBL643086 | 0.71 | ALOX15 (0.50) | POLBALOX15TSHRHSD17B10MEN1 | |
| SCHEMBL207531 | 0.71 | AHR (0.50) | AHRALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL208359 | 0.71 | CYP1A2 (0.48) | NOS1ALDH1A1PSMB8HPGDALOX15 | |
| SCHEMBL207737 | 0.71 | CYP2A6 (0.50) | AHRNR4A2NOS1ALDH1A1HPGD | |
| SCHEMBL4694683 | 0.71 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL2715277 | 0.70 | ALDH1A1 (0.39) | ALDH1A1HPGDTSHRHSD17B10MEN1 | |
| SCHEMBL207242 | 0.69 | ALDH1A1 (0.56) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL1188 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201911-A | Compounds and their use as GPR183 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-116438160-A | Carbamoyl compounds for the treatment of viral infections | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | claimed |
| EP-4204393-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | claimed |
| EP-3021847-B1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2023-06-07 | — | — | EP | claimed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | claimed |
| CN-112939977-A | Halogenated nitrogen heterocyclic matrine derivative and preparation method and application thereof | 仲恺农业工程学院 | 2021-06-11 | — | — | CN | claimed |
| CN-105611930-B | Spiro quinoxaline derivatives as non-apoptotic regulated cell death inhibitors | 亥姆霍兹慕尼黑中心-德国环境与健康研究中心（股份有限公司） | 2021-03-02 | — | — | CN | claimed |
| EP-3321262-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-13 | — | — | EP | claimed |
| CN-106349217-B | Serine/threonine kinase inhibitors | 阵列生物制药公司 | 2020-08-28 | — | — | CN | claimed |
| US-10280179-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2019-05-07 | — | — | US | claimed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | claimed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | claimed |
| WO-2002072548-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-19 | — | — | WO | claimed |
| WO-2002048102-A2 | ISOCOUMARIN INHIBITING PRODUCTION OF AMYLOID PEPTIDE, PREPARATION, COMPOSITIONS CONTAINING SAME AND USES | TROPHOS (FR) | 2002-06-20 | — | — | WO | claimed |
| WO-2001096304-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001096296-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001096323-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2000061631-A1 | MODIFIED PENTAPEPTIDE ANTAGONISTS OF THE ATRIAL NATRIURETIC PEPTIDE CLEARANCE RECEPTOR | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | claimed |
| US-5698576-A | POSSESS ANTI-ULCER AND 5-LIPOXYGENASE INHIBITORY ACTIVITIES | SANKYO COMPANY, LIMITED (JP) | 1997-12-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280179-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | F7 4590/4885F3 3303/4885AHR 2750/4885 |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, AKR1B1, AKR1D1 | F7 4500/4885F3 3873/4885AHR 2958/4885 |
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | F7 277/4885F3 154/4885AHR 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.